Covidien
COV announced a definitive agreement to acquire CV
Ingenuity. The companies expect to complete the acquisition
in the first calendar quarter of 2013. Financial terms of the
transaction were not disclosed.
CV Ingenuity, a privately-held company based in Fremont, CA, is focused
on improving patient outcomes in the treatment of peripheral arterial
disease (PAD) by providing solutions to relieve vascular obstructions,
inhibit restenosis, and allow natural vessel healing. The company's core
technology, while still in the investigational phase, is a Drug Coated
Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release
system.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in